manilatimes28 天
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Phase 1 therapeutic clinical study of 177Lu-labelled RAD 202 for the treatment of HER2-expressing solid tumors. The open-label Phase 1 trial, entitled 'HEAT' (HER2 Antibody Therapy with Lutetium-177), ...